Compare Novo Nordisk A/S (NVO) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Uranium Energy Corp — how do they compare? Novo Nordisk A/S trades at $46.19 (market cap $207.85B), while Uranium Energy Corp trades at $11.45 (market cap $5.67B). The key difference: Novo Nordisk A/S is far larger — about 36.7× Uranium Energy Corp's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| NVO | UEC | |
|---|---|---|
Market Cap | $207.85B | $5.67B |
Sector | Health | Energy |
52-Week High | $63.98 | $20.14 |
52-Week Low | $35.29 | $9.04 |
Enterprise Value | $222.55B | $5.18B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
UEC trades at $11.64, up 2.28% today, with a bullish technical signal from moving averages. The company reported a net loss of $87.66 million in 2025 despite $66.84 million revenue, with negative profit margins and cash flow challenges. Recent news highlights insider selling and ongoing uranium market optimism. Analyst consensus is strongly bullish with 87.5% buy ratings, though fundamentals show significant financial strain.
UEC presents high-risk exposure to uranium market growth with substantial operational losses and negative cash flow from operations. The stock's premium valuation (P/S 267.84) relies heavily on future nuclear energy adoption, while current financials indicate dependency on financing activities. Near-term catalysts include production ramp-up and licensing approvals, but execution risks and cost pressures remain elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
